Claim OwnershipEvidence Based Medicine presented by InpharmD™
Subscribed: 2Played: 220
Subscribe
Description
We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.
74 Episodes
Reverse
Join InpharmD as we discuss the role of apixaban in peripheral artery disease.
Join us as we discuss the data surrounding newly approved antifungal agent, rezafungin. Interested in learning more? Join our CE on rezafungin on July 27th at 12:00 PM EST - open to all pharmacists!
Every month, InpharmD creates a continuing-education (CE) class on the most commonly asked drug information question and the related evidence. Our podcast offers a sneak peak into our CE as we briefly discuss the topic. Episode-2 looks at the safety and efficacy of lecanemab in the treatment of Alzheimer’s dementia.
Many hospitals have been dealing with the recent oxytocin shortage. With this episode, we discuss possible alternatives and adjuncts to oxytocin, based on the evidence available.
A randomized clinical trial conducted to assess time-restricted eating with calorie restriction as compared with daily calorie restriction alone for the effects on weight loss and metabolic risk factors in obese patients.
A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer vaccine) booster.
Join us as we discuss the evidence surrounding tirzepatide for weight loss in diabetic patient populations.
InpharmD's EBM podcast focuses on commonly asked drug information questions. Every day, our queue gets tons of new questions asked from providers all around the country. One question that’s been garnering a lot of views from our users right now is which atypical antipsychotics are associated with the lowest and highest risk of QT prolongation.
Join InpharmD as we discuss the safety and efficacy of two FDA-approved RSV vaccines, Arexvy and Abrysvo.
Join InpharmD as we discuss the data on perioperative duloxetine (Cymbalta) during orthopedic surgery for pain reduction. Interested in the full data response? Read here!
Tune in as we discuss the PROVENT trial and the on-going TACKLE trial to determine whether or not Evusheld can increase cardiovascular events.
A regression analysis conducted in Israel showed that a fourth dose appeared to increase the protection against severe illness relative to three doses that were administered more than 4 months earlier. Further studies are needed before applying this to a larger population.
A multicenter, randomized, open label, non-inferiority trial conducted to test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections (UTI) with the current standard prophylaxis of daily low dose antibiotics.
A cohort study conducted to estimate the rate of breast cancer overdiagnosis in contemporary mammography practice accounting for the detection of nonprogressive cancer.
A prospective, double blind, superiority, randomized placebo-controlled trial conducted to confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks.
A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.
A double-blind, randomized, placebo-controlled trial conducted to evaluate the efficacy and safety of a 3-day course of remdesivir in high-risk, non-hospitalized patients with COVID-19.
A single-blind, multicenter, randomized, controlled trial conducted to evaluate the efficacy of financial incentives dependent on continuous smoking abstinence on smoking cessation and birth outcomes among pregnant smokers.
An open-label, randomized, parallel-group, adaptive design with blinded outcome adjudication trial conducted to compare the efficacy and safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty.
The first in-human, phase 1, randomized, double-blind, placebo-controlled study conducted to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of molnupiravir in healthy subjects.
Comments
Download from Google Play
Download from App Store
United States